Safety, Efficacy, and Effectiveness of Coronary Sinus Reducer Implantation in Refractory Angina: A Meta-Analysis | JACC: Cardiovascular Interventions

Percutaneous coronary intervention, coronary artery bypass grafting and mortality from acute myocardial infarction in EU15+ countries, 2006–2020 @BMJ_Open

Under appreciated by many: in some hospital systems, the procedural cardiologists are the most conservative. Most aggressive can be the referral docs.

This video witnesses the chaotic rhythm of ventricular fibrillation, a precursor to sudden cardiac arrest. Treatment : immediate defibrillation and cpr Source: @medi_cosity

Delighted to share the final typeset version of the 1st Joint EACVI/ACVC/@EACTAIC Expert Consensus on Cardiac Ultrasound in Cardiovascular Emergency & Critical Care — now the most-read article in EHJ–CV Imaging! 🫀 #EACVI #EchoFirst #POCUS #CriticalCare Open access 👇

The main reason to read this paper is as an example of observational study run amok “Among 253 pts at a single center…” With all due respect, please, resist the urge to do (and publish) such folly. Look at the early curve separation https://t.co/zUnkmvQmGA

🚀 #ESCCongress 2025 was a great success! Honoured to serve as Faculty & Chair in sessions on HF, cardiogenic shock & novel #echofirst techniques. 📊 As #EACVI Secretary, we had a very fruitful board meeting where discussed the upcoming Vienna Congress (11–13 Dec) — EuroEcho,

Really enjoyed @drjohnm’s take on our Coronary Sinus Reducer meta-analysis → https://t.co/tP5gcC2it5 CSR shows promise. COSIRA-II may give conclusive answers. Novel procedures need to be tested in double-blind RCTs where feasible. #EBM 📝 Our paper:

https://t.co/2l8MWMNezY

Heartflow raises $364M with IPO, rings Nasdaq’s opening bell #cardiology #AI #imaging @Heartflow

Coronary Sinus Reducer Shows Promise, With Caveats

Coronary sinus reducer implantation may be safe & feasible, w/ promising antianginal efficacy in patients w/ refractory angina, according to a meta-analysis published in #JACCINT. However, larger trials are needed to assess efficacy. Read more: https://t.co/6jVtZIAJ1s

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis https://t.co/fw4hNzLzVc

Coronary sinus reducer linked to improvements in patients with refractory angina—but questions remain #cardiology

🚨 Just out in @JACCJournals: Our meta-analysis on the safety, efficacy & effectiveness of the Coronary Sinus Reducer (#CSR) for #RefractoryAngina 🫀 📄 Open access: https://t.co/xa7Z7lW0AF @rallamee @CardioKarsh @MikeFoley89 #Cardiology #InterventionalCardiology

Hot off the press!! 🔥 🗞️ Our editorial comment about the Coronary Sinus Reducer device with @DLBHATTMD at @JACCJournals. A promising device for our patients with refractory angina 💊@SinaiCards @MountSinaiHeart https://t.co/GoRoTiffWh

Schematic representation of the anatomic distribution of focal atrial tachycardias😍

📢 New in Reviews in Cardiovascular Medicine #Heart failure affects 56M people worldwide. #Cardiometabolic risk factors like #hypertension & #obesity play a key role in its progression. Understanding these links is vital for better treatments. Dive into the latest insights!

#Heart failure affects 56M people worldwide. #Cardiometabolic risk factors like #hypertension & #obesity play a key role in its progression. Understanding these links is vital for better treatments. Dive into the latest insights! ✍️@CardioKarsh, et al 🔗 https://t.co/kfx9KYSEPz

Very delighted that our new book is finally published today by @ElsevierConnect. ‘Clinical Applications of Echo Doppler Haemodynamics’ with my amazing co-editor @argulian 100 cases with deep dive into many intriguing pearls and pitfalls of Doppler echocardiography. With the